{"id":770404,"date":"2023-07-17T19:04:48","date_gmt":"2023-07-17T23:04:48","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/priveterra-acquisition-corp-announces-authorization-to-list-on-nyse-upon-completion-of-business-combination-with-aeon-biopharma-inc\/"},"modified":"2023-07-17T19:04:48","modified_gmt":"2023-07-17T23:04:48","slug":"priveterra-acquisition-corp-announces-authorization-to-list-on-nyse-upon-completion-of-business-combination-with-aeon-biopharma-inc","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/priveterra-acquisition-corp-announces-authorization-to-list-on-nyse-upon-completion-of-business-combination-with-aeon-biopharma-inc\/","title":{"rendered":"Priveterra Acquisition Corp. Announces Authorization to List on NYSE Upon Completion of Business Combination with AEON Biopharma, Inc."},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Priveterra Acquisition Corp. Announces Authorization to List on NYSE Upon Completion of Business Combination with AEON Biopharma, Inc.<\/b><\/p>\n<p>FORT LAUDERDALE, Fla.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nPriveterra Acquisition Corp. (Nasdaq: PMGM) (\u201cPriveterra\u201d and, after the consummation of its pending business combination (the \u201cBusiness Combination\u201d) and following its name change to AEON Biopharma, Inc., \u201cNew AEON\u201d) today announced that NYSE Regulation, on July 13, 2023, authorized New AEON common stock (\u201cNew AEON Common Stock\u201d) and New AEON warrants to be listed on NYSE American LLC (\u201cNYSE\u201d) upon the Business Combination with AEON Biopharma, Inc., (\u201cAEON\u201d) following which AEON will be a wholly owned subsidiary of Priveterra and Priveterra will change its name to AEON Biopharma, Inc.<\/p>\n<p id=\"news-body-cta\">This press release features multimedia. View the full release here: <a href=\"https:\/\/www.businesswire.com\/news\/home\/20230717921274\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20230717921274\/en\/<\/a><\/p>\n<p>\nTrading is expected to begin on NYSE on July 24, 2023, under the new ticker symbol \u201cAEON\u201d for the New AEON Common Stock following the consummation of the Business Combination, which is expected to occur on July 21, 2023, subject to satisfaction or waiver of standard, customary closing conditions.<\/p>\n<p>\nAs of July 17, 2023, Priveterra\u2019s public stockholders holding 1,681,348 shares, out of a total of 2,002,272 shares, of Class A common stock validly elected to redeem their public shares for a full pro rata portion of the trust account holding the proceeds from Priveterra\u2019s initial public offering, leaving 320,924 shares remaining. The redemption price as of July 17, 2023 is approximately $10.62.<\/p>\n<p>\nPriveterra will be automatically accepting requests by stockholders to withdraw their previously submitted redemption requests until 5:00 p.m. Eastern Time on July 20, 2023.<\/p>\n<p>\nNo action is required by existing PMGM shareholders with respect to the ticker symbol or exchange listing change.<\/p>\n<p><b>About Priveterra Acquisition Corp.<\/b><\/p>\n<p>\nPriveterra Acquisition Corp. (NASDAQ: PMGM) is a blank-check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses in life sciences. Priveterra is sponsored by Robert Palmisano and Priveterra Capital, LLC.<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p>\nThis Current Report on Form 8-K includes \u201cforward-looking statements\u201d within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events involving, or future performance of, the Company or AEON. In some cases, you can identify forward-looking statements by terminology such as \u201cpro forma\u201d, \u201cmay\u201d, \u201cshould\u201d, \u201ccould\u201d, \u201cmight\u201d, \u201cplan\u201d, \u201cpossible\u201d, \u201cproject\u201d, \u201cstrive\u201d, \u201cbudget\u201d, \u201cforecast\u201d, \u201cexpect\u201d, \u201cintend\u201d, \u201cwill\u201d, \u201cestimate\u201d, \u201canticipate\u201d, \u201cbelieve\u201d, \u201cpredict\u201d, \u201cpotential\u201d or \u201ccontinue\u201d, or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by the Company and its management, and AEON and its management, as the case may be, are inherently uncertain. Certain risks and uncertainties are set forth in the section entitled \u201cRisk Factors\u201d and \u201cCautionary Note Regarding Forward-Looking Statements\u201d in the Company\u2019s final prospectus dated February 11, 2021, relating to its IPO and other risks and uncertainties indicated from time to time in the definitive proxy statement to be delivered to the Company\u2019s stockholders and related S-4 Registration Statement, including those set forth under \u201cRisk Factors\u201d therein, and other documents filed to be filed with the SEC by the Company.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230717921274r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20230717921274\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20230717921274\/en\/<\/a><\/span><\/p>\n<p><b>Investor Contact:<br \/>\n<\/b><br \/>Priveterra Acquisition Corp.<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:spac@priveterra.com\">spac@priveterra.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United States North America Florida<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Publishing Finance Marketing Advertising Communications Professional Services Small Business General Health Health Search Engine Marketing<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230717921274\/en\/1843182\/3\/AEON.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230717921274\/en\/1843183\/3\/Priveterra.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Priveterra Acquisition Corp. Announces Authorization to List on NYSE Upon Completion of Business Combination with AEON Biopharma, Inc. FORT LAUDERDALE, Fla.&#8211;(BUSINESS WIRE)&#8211; Priveterra Acquisition Corp. (Nasdaq: PMGM) (\u201cPriveterra\u201d and, after the consummation of its pending business combination (the \u201cBusiness Combination\u201d) and following its name change to AEON Biopharma, Inc., \u201cNew AEON\u201d) today announced that NYSE Regulation, on July 13, 2023, authorized New AEON common stock (\u201cNew AEON Common Stock\u201d) and New AEON warrants to be listed on NYSE American LLC (\u201cNYSE\u201d) upon the Business Combination with AEON Biopharma, Inc., (\u201cAEON\u201d) following which AEON will be a wholly owned subsidiary of Priveterra and Priveterra will change its name to AEON Biopharma, Inc. This press release features multimedia. View the full release &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/priveterra-acquisition-corp-announces-authorization-to-list-on-nyse-upon-completion-of-business-combination-with-aeon-biopharma-inc\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Priveterra Acquisition Corp. Announces Authorization to List on NYSE Upon Completion of Business Combination with AEON Biopharma, Inc.&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-770404","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Priveterra Acquisition Corp. Announces Authorization to List on NYSE Upon Completion of Business Combination with AEON Biopharma, Inc. - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/priveterra-acquisition-corp-announces-authorization-to-list-on-nyse-upon-completion-of-business-combination-with-aeon-biopharma-inc\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Priveterra Acquisition Corp. Announces Authorization to List on NYSE Upon Completion of Business Combination with AEON Biopharma, Inc. - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Priveterra Acquisition Corp. Announces Authorization to List on NYSE Upon Completion of Business Combination with AEON Biopharma, Inc. FORT LAUDERDALE, Fla.&#8211;(BUSINESS WIRE)&#8211; Priveterra Acquisition Corp. (Nasdaq: PMGM) (\u201cPriveterra\u201d and, after the consummation of its pending business combination (the \u201cBusiness Combination\u201d) and following its name change to AEON Biopharma, Inc., \u201cNew AEON\u201d) today announced that NYSE Regulation, on July 13, 2023, authorized New AEON common stock (\u201cNew AEON Common Stock\u201d) and New AEON warrants to be listed on NYSE American LLC (\u201cNYSE\u201d) upon the Business Combination with AEON Biopharma, Inc., (\u201cAEON\u201d) following which AEON will be a wholly owned subsidiary of Priveterra and Priveterra will change its name to AEON Biopharma, Inc. This press release features multimedia. View the full release &hellip; Continue reading &quot;Priveterra Acquisition Corp. Announces Authorization to List on NYSE Upon Completion of Business Combination with AEON Biopharma, Inc.&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/priveterra-acquisition-corp-announces-authorization-to-list-on-nyse-upon-completion-of-business-combination-with-aeon-biopharma-inc\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-17T23:04:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230717921274r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/priveterra-acquisition-corp-announces-authorization-to-list-on-nyse-upon-completion-of-business-combination-with-aeon-biopharma-inc\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/priveterra-acquisition-corp-announces-authorization-to-list-on-nyse-upon-completion-of-business-combination-with-aeon-biopharma-inc\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Priveterra Acquisition Corp. Announces Authorization to List on NYSE Upon Completion of Business Combination with AEON Biopharma, Inc.\",\"datePublished\":\"2023-07-17T23:04:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/priveterra-acquisition-corp-announces-authorization-to-list-on-nyse-upon-completion-of-business-combination-with-aeon-biopharma-inc\\\/\"},\"wordCount\":618,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/priveterra-acquisition-corp-announces-authorization-to-list-on-nyse-upon-completion-of-business-combination-with-aeon-biopharma-inc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230717921274r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/priveterra-acquisition-corp-announces-authorization-to-list-on-nyse-upon-completion-of-business-combination-with-aeon-biopharma-inc\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/priveterra-acquisition-corp-announces-authorization-to-list-on-nyse-upon-completion-of-business-combination-with-aeon-biopharma-inc\\\/\",\"name\":\"Priveterra Acquisition Corp. Announces Authorization to List on NYSE Upon Completion of Business Combination with AEON Biopharma, Inc. - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/priveterra-acquisition-corp-announces-authorization-to-list-on-nyse-upon-completion-of-business-combination-with-aeon-biopharma-inc\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/priveterra-acquisition-corp-announces-authorization-to-list-on-nyse-upon-completion-of-business-combination-with-aeon-biopharma-inc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230717921274r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2023-07-17T23:04:48+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/priveterra-acquisition-corp-announces-authorization-to-list-on-nyse-upon-completion-of-business-combination-with-aeon-biopharma-inc\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/priveterra-acquisition-corp-announces-authorization-to-list-on-nyse-upon-completion-of-business-combination-with-aeon-biopharma-inc\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/priveterra-acquisition-corp-announces-authorization-to-list-on-nyse-upon-completion-of-business-combination-with-aeon-biopharma-inc\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230717921274r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230717921274r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/priveterra-acquisition-corp-announces-authorization-to-list-on-nyse-upon-completion-of-business-combination-with-aeon-biopharma-inc\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Priveterra Acquisition Corp. Announces Authorization to List on NYSE Upon Completion of Business Combination with AEON Biopharma, Inc.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Priveterra Acquisition Corp. Announces Authorization to List on NYSE Upon Completion of Business Combination with AEON Biopharma, Inc. - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/priveterra-acquisition-corp-announces-authorization-to-list-on-nyse-upon-completion-of-business-combination-with-aeon-biopharma-inc\/","og_locale":"en_US","og_type":"article","og_title":"Priveterra Acquisition Corp. Announces Authorization to List on NYSE Upon Completion of Business Combination with AEON Biopharma, Inc. - Market Newsdesk","og_description":"Priveterra Acquisition Corp. Announces Authorization to List on NYSE Upon Completion of Business Combination with AEON Biopharma, Inc. FORT LAUDERDALE, Fla.&#8211;(BUSINESS WIRE)&#8211; Priveterra Acquisition Corp. (Nasdaq: PMGM) (\u201cPriveterra\u201d and, after the consummation of its pending business combination (the \u201cBusiness Combination\u201d) and following its name change to AEON Biopharma, Inc., \u201cNew AEON\u201d) today announced that NYSE Regulation, on July 13, 2023, authorized New AEON common stock (\u201cNew AEON Common Stock\u201d) and New AEON warrants to be listed on NYSE American LLC (\u201cNYSE\u201d) upon the Business Combination with AEON Biopharma, Inc., (\u201cAEON\u201d) following which AEON will be a wholly owned subsidiary of Priveterra and Priveterra will change its name to AEON Biopharma, Inc. This press release features multimedia. View the full release &hellip; Continue reading \"Priveterra Acquisition Corp. Announces Authorization to List on NYSE Upon Completion of Business Combination with AEON Biopharma, Inc.\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/priveterra-acquisition-corp-announces-authorization-to-list-on-nyse-upon-completion-of-business-combination-with-aeon-biopharma-inc\/","og_site_name":"Market Newsdesk","article_published_time":"2023-07-17T23:04:48+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230717921274r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/priveterra-acquisition-corp-announces-authorization-to-list-on-nyse-upon-completion-of-business-combination-with-aeon-biopharma-inc\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/priveterra-acquisition-corp-announces-authorization-to-list-on-nyse-upon-completion-of-business-combination-with-aeon-biopharma-inc\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Priveterra Acquisition Corp. Announces Authorization to List on NYSE Upon Completion of Business Combination with AEON Biopharma, Inc.","datePublished":"2023-07-17T23:04:48+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/priveterra-acquisition-corp-announces-authorization-to-list-on-nyse-upon-completion-of-business-combination-with-aeon-biopharma-inc\/"},"wordCount":618,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/priveterra-acquisition-corp-announces-authorization-to-list-on-nyse-upon-completion-of-business-combination-with-aeon-biopharma-inc\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230717921274r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/priveterra-acquisition-corp-announces-authorization-to-list-on-nyse-upon-completion-of-business-combination-with-aeon-biopharma-inc\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/priveterra-acquisition-corp-announces-authorization-to-list-on-nyse-upon-completion-of-business-combination-with-aeon-biopharma-inc\/","name":"Priveterra Acquisition Corp. Announces Authorization to List on NYSE Upon Completion of Business Combination with AEON Biopharma, Inc. - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/priveterra-acquisition-corp-announces-authorization-to-list-on-nyse-upon-completion-of-business-combination-with-aeon-biopharma-inc\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/priveterra-acquisition-corp-announces-authorization-to-list-on-nyse-upon-completion-of-business-combination-with-aeon-biopharma-inc\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230717921274r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2023-07-17T23:04:48+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/priveterra-acquisition-corp-announces-authorization-to-list-on-nyse-upon-completion-of-business-combination-with-aeon-biopharma-inc\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/priveterra-acquisition-corp-announces-authorization-to-list-on-nyse-upon-completion-of-business-combination-with-aeon-biopharma-inc\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/priveterra-acquisition-corp-announces-authorization-to-list-on-nyse-upon-completion-of-business-combination-with-aeon-biopharma-inc\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230717921274r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230717921274r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/priveterra-acquisition-corp-announces-authorization-to-list-on-nyse-upon-completion-of-business-combination-with-aeon-biopharma-inc\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Priveterra Acquisition Corp. Announces Authorization to List on NYSE Upon Completion of Business Combination with AEON Biopharma, Inc."}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/770404","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=770404"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/770404\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=770404"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=770404"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=770404"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}